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Clinical PerspectiveWhat Is New?In a large contemporary US database, women underwent aortic valve replacement for aortic stenosis less than men.Aortic valve replacement in women was associated with worse in‐hospital mortality and higher cost compared with men.What Are the Clinical Implications?Women had worse outcomes with aortic valve replacement compared with men, and this was consistent over 12 years.These data should be considered when assessing suitability of women for transcatheter or surgical aortic valve replacement.

Introduction {#jah32569-sec-0008}
============

Sex‐related differences in the incidence, pathophysiology, presentation, treatment, and outcomes of cardiovascular diseases including aortic stenosis (AS) have been studied extensively.[1](#jah32569-bib-0001){ref-type="ref"} Aortic valve replacement (AVR) has historically been the gold standard treatment of calcific AS.[2](#jah32569-bib-0002){ref-type="ref"} The outcomes of AVR have improved significantly nationwide in the past decade.[3](#jah32569-bib-0003){ref-type="ref"} Several studies have assessed the differential impact of sex on outcomes of AVR but yielded conflicting results.[4](#jah32569-bib-0004){ref-type="ref"}, [5](#jah32569-bib-0005){ref-type="ref"}, [6](#jah32569-bib-0006){ref-type="ref"}, [7](#jah32569-bib-0007){ref-type="ref"}, [8](#jah32569-bib-0008){ref-type="ref"}, [9](#jah32569-bib-0009){ref-type="ref"}, [10](#jah32569-bib-0010){ref-type="ref"}, [11](#jah32569-bib-0011){ref-type="ref"}, [12](#jah32569-bib-0012){ref-type="ref"}, [13](#jah32569-bib-0013){ref-type="ref"} The interest in examining the sex gap in AS patients has been renewed with the introduction and widespread adoption of transcatheter AVR (TAVR). Recently, a report from the American College of Cardiology (ACC) and TVT registry and a large meta‐analysis showed superior outcomes with TAVR in women compared with men.[1](#jah32569-bib-0001){ref-type="ref"}, [14](#jah32569-bib-0014){ref-type="ref"} We hypothesized that female patients have worse outcomes following AVR compared with propensity‐matched male patients. We propose that if our hypothesis is true, perhaps women should be offered TAVR over surgical AVR at a lower threshold compared with men, given the mounting evidence of better outcomes of TAVR in women versus men.

We aimed to utilize a large national database to investigate (1) trends of AVR utilization in women versus men over a 12‐year period, (2) sex differences in risk profile of patients undergoing AVR, (3) in‐hospital morbidity and mortality of AVR in men versus women and (4) the trends of these outcomes over time.

Methods {#jah32569-sec-0009}
=======

Study Data {#jah32569-sec-0010}
----------

The Nationwide Inpatient Sample (NIS) was used to derive patient‐relevant information between January 2003 and December 2014. The NIS is the largest publicly available all‐payer administrative claims--based database and contains information about patient discharges from ≈1000 nonfederal hospitals in 45 states. It contains clinical and resource utilization information on 5 million to 8 million discharges annually, with safeguards to protect the privacy of individual patients, physicians, and hospitals. These data are stratified to represent ≈20% of US inpatient hospitalizations across different hospital and geographic regions (random sample). National estimates of the entire US hospitalized population were calculated using the Agency for Healthcare Research and Quality sampling and weighting method.

Study Population {#jah32569-sec-0011}
----------------

Patients with a discharge diagnosis of aortic valve stenosis (*International Classification of Diseases, Ninth Revision, Clinical Modification* \[ICD‐9‐CM\] codes 424.1, 395.0, 395.2, 396.2, 746.3) who underwent AVR (ICD‐9‐CM procedure code 35.20 and 35.21) during the study period were identified from the NIS database.

Trends of Utilization and Outcomes of AVR {#jah32569-sec-0012}
-----------------------------------------

The trend of surgical AVR during the 12‐year study period were assessed using weighted values (national estimates). The Mann--Kendall test was used to evaluate trends of AVR in male and female patients. Baseline comorbidities were described, and in‐hospital morbidity and mortality were assessed and compared between sexes.

Comparative Outcomes Analysis {#jah32569-sec-0013}
-----------------------------

To account for potential confounding factors and to reduce the effect of selection bias, a propensity score--matching model was developed using logistic regression to derive 2 matched groups for comparative outcomes analysis. After excluding patients who underwent concomitant cardiac surgery, patients who underwent "isolated" AVR were entered into a nearest neighbor 1:1 variable ratio, parallel, balanced propensity score--matching model using a caliper of 0.01 to ensure perfect matching. Table [S1](#jah32569-sup-0001){ref-type="supplementary-material"} lists all covariates that we included in the propensity score models. We performed multiple imputations to impute missing values for race (missing in 16% of observations) using the fully conditional specification method (an iterative Markov chain Monte Carlo algorithm) using age, sex, insurance status, comorbid conditions, hospital region, and clinical characteristics. This method adheres to the recommendations provided by the Healthcare Cost and Utilization Project (HCUP)[15](#jah32569-bib-0015){ref-type="ref"} for handling missing racial data. To estimate the cost of hospitalization, the NIS data were merged with cost‐to‐charge ratios available from the HCUP. We estimated the cost of each inpatient stay by multiplying the total hospital charge with cost‐to‐charge ratios.

The primary end point was in‐hospital death. Secondary outcomes included procedural mortality (defined as death occurring on the same hospital day as AVR), vascular complications, pacemaker implantation, transient ischemic attack, stroke, blood transfusion, acute kidney injury requiring dialysis, cardiac tamponade, hospital length of stay, cost of hospitalization, and discharge disposition. Subgroup analyses were performed for the outcomes of in‐hospital mortality in the propensity score--matched groups to assess the impact of age, age, race, teaching status, and primary and selected relevant major comorbidities on the differences in mortality between male and female participants.

Statistical Analyses {#jah32569-sec-0014}
--------------------

Descriptive statistics are presented as frequencies with percentages for categorical variables. Mean, standard deviation, median, and interquartile range were reported for continuous measures. Baseline characteristics were compared using a Pearson χ^2^ test and Fisher exact test for categorical variables and an independent‐samples *t* test for continuous variables. Trend weights accounting for changes in the NIS sampling design are available only for data between 1998 and 2011. For 2012 and 2013, trend weights were not available, and the standard survey weights were used. Matched categorical variables were presented as frequencies with percentages and compared using the McNemar test. Matched continuous variables were presented as means with standard deviations and compared using a paired‐samples *t* test. A type I error rate of \<0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 24 (IBM Corp) and R, version 3.3.1 (R Foundation for Statistical Computing).

Results {#jah32569-sec-0015}
=======

In total, 166 809 patients underwent AVR between 2003 and 2014 (weighted national estimates: 825 721 patients), of whom 105 106 (63%) were male and 61 703 (37%) were female. The utilization disparity in AVR was constant throughout the study period (Figure [1](#jah32569-fig-0001){ref-type="fig"}). Baseline characteristic profiles were distinctly different between men and women, as detailed in Table [1](#jah32569-tbl-0001){ref-type="table-wrap"}. Compared with men, women were older (70±13 versus 67±14 years, *P*\<0.001) and had higher rates of hypertension, diabetes mellitus, chronic obstructive lung disease, and anemia. In contrast, coronary and peripheral arterial disease and history of prior sternotomy were more prevalent in men. The majority of AVRs (67.4%) were performed at teaching hospitals, and 32.8% were performed during an unplanned admission. More women had Medicare/Medicaid insurance compared with men (75.4% versus 63.6%, *P*\<0.001). Bioprosthetic valve utilization increased from 46% in 2003 to 65% in 2014, and this upward trend was similar for men and women (Figure [1](#jah32569-fig-0001){ref-type="fig"}). Concomitant cardiac surgery was common (48.5%); men were more likely to undergo simultaneous coronary artery bypass grafting (42.8% versus 33.6%, *P*\<0.001), whereas women were more likely to undergo simultaneous mitral valve replacement (8.7% versus 4.8%, *P*\<0.001). In‐hospital mortality was significantly higher in women than in men (5.6% versus 4%, *P*\<0.001; Table [2](#jah32569-tbl-0002){ref-type="table-wrap"}). Women had higher rates of vascular complications (5.8% versus 5.5%, *P*\<0.001), permanent pacemaker implantation (7.2% versus 6.6%, *P*\<0.001), and blood transfusion (40.9% versus 35.4%, *P*\<0.001). Rates of stroke were similar in men and women (2.7% versus 2.9%, *P*=0.096).

![Utilization trends of surgical aortic valve replacement in men and women between 2003 and 2014. AVR indicates aortic valve replacement.](JAH3-6-e006370-g001){#jah32569-fig-0001}

###### 

Characteristics of Patients Undergoing Surgical AVR Between 2003 and 2014 (Including Combined Procedures)

  Characteristic                        All Patients (n=166 809)   Male (n=105 106)   Female (n=61 703)   *P* Value
  ------------------------------------- -------------------------- ------------------ ------------------- -----------
  Age, y, mean (SD)                     68 (14)                    67 (14)            70 (13)             \<0.0001
  Race, n (%)                           \<0.0001                                                          
  White                                 139 714 (83.8)             87 946 (83.7)      51 768 (83.9)       
  Black                                 8516 (5.1)                 5186 (4.9)         3330 (5.4)          
  Hispanic                              10 084 (6)                 6745 (6.4)         3339 (5.4)          
  Medical comorbidity, n (%)                                                                              
  Hypertension                          106 535 (63.9)             66 374 (63.1)      40 161 (65.1)       \<0.0001
  Diabetes mellitus                     42 900 (25.7)              26 503 (25.2)      16 397 (26.6)       \<0.0001
  Prior sternotomy                      7195 (4.3)                 5592 (5.3)         1603 (2.6)          \<0.0001
  Chronic pulmonary disease             33 513 (20.1)              20 342 (19.4)      13 171 (21.3)       \<0.0001
  Atrial fibrillation/flutter           72 999 (43.8)              45 971 (43.7)      27 028 (43.8)       0.794
  Cardiogenic shock                     6565 (3.9)                 4051 (3.9)         2514 (4.1)          0.026
  Anemia                                30 713 (18.4)              18 366 (17.5)      12 347 (20)         \<0.0001
  Coagulopathy                          39 755 (23.8)              25 040 (23.8)      14 715 (23.8)       0.91
  Conduction abnormalities              5438 (3.3)                 3578 (3.4)         1860 (3)            \<0.0001
  Peripheral vascular disease           29 535 (17.7)              20 115 (19.1)      9420 (15.3)         \<0.0001
  Chronic renal disease                 21 029 (12.6)              14 239 (13.5)      6790 (11)           \<0.0001
  Coronary artery disease               82 622 (49.5)              55 339 (52.7)      27 283 (44.2)       \<0.0001
  Metastatic cancer                     293 (0.2)                  207 (0.2)          86 (0.1)            0.007
  Liver disease                         2542 (1.5)                 1740 (1.7)         802 (1.3)           \<0.0001
  Aortic prosthesis                                                                                       
  Bioprosthetic                         100 999 (60.50)            63 399 (60.3)      37 600 (60.9)       0.013
  Mechanical                            66 005 (39.6)              41 816 (39.8)      24 189 (39.2)       0.019
  Concomitant procedures, n (%)                                                                           
  Coronary artery bypass                65 781 (39.4)              44 960 (42.8)      20 821 (33.7)       \<0.0001
  Percutaneous coronary intervention    699 (0.4)                  461 (0.4)          238 (0.4)           0.106
  Mitral valve valvuloplasty            5278 (3.2)                 3406 (3.2)         1872 (3)            0.02
  Mitral valve replacement              10 441 (6.3)               5050 (4.8)         5391 (8.7)          \<0.0001
  Annuloplasty                          5278 (3.2)                 3406 (3.2)         1872 (3)            0.02
  Open ASD\\VSD repair                  3403 (2)                   2108 (2)           1295 (2.1)          0.194
  IABP/LV assist device use             7462 (4.5)                 4905 (4.7)         2557 (4.1)          \<0.0001
  Hospital characteristics, n (%)                                                                         
  Teaching hospital                     112 372 (67.4)             71 079 (67.6)      41 293 (66.9)       0.003
  Hospital bed size                     0.074                                                             
  Small                                 11 249 (6.7)               6993 (6.7)         4256 (6.9)          
  Medium                                30 336 (18.2)              19 226 (18.3)      11 110 (18)         
  Large                                 125 224 (75.1)             78 887 (75.1)      46 337 (75.1)       
  Rural location                        5924 (3.6)                 3782 (3.6)         2142 (3.5)          0.177
  Nonelective admission status, n (%)   54 717 (32.8)              34 718 (33)        19 999 (32.4)       0.009
  Primary payer, n (%)                  \<0.0001                                                          
  Medicare/Medicaid                     113 333 (67.9)             66 835 (63.6)      46 498 (75.4)       
  Private including HMO                 46 358 (27.8)              33 143 (31.5)      13 215 (21.4)       
  Self‐pay/no charge/other              7118 (4.3)                 5128 (4.9)         1990 (3.2)          
  Median household income, n (%)        \<0.0001                                                          
  0 to 25th percentiles                 35 947 (21.5)              21 889 (20.8)      14 058 (22.8)       
  26th to 50th percentiles              43 307 (26)                26 958 (25.6)      16 349 (26.5)       
  51st to 75th percentiles              43 431 (26)                27 572 (26.2)      15 859 (25.7)       
  76th to 100th percentiles             44 124 (26.5)              28 687 (27.3)      15 437 (25)         

ASD indicates atrial septal defect; AVR, aortic valve replacement; HMO, health maintenance organization; IABP, intra‐aortic balloon pump; LV, left ventricular; VSD, ventricular septal defect.

###### 

In‐Hospital Outcomes of Patients Undergoing Surgical AVR Between 2003 and 2014 (Including Combined Procedures)

                                             All Patients (n=166 809)   Male (n=105 106)   Female (n=61 703)   *P* Value
  ------------------------------------------ -------------------------- ------------------ ------------------- -----------
  Clinical outcome, n (%)                                                                                      
  In‐hospital death                          7591 (4.6)                 4165 (4)           3426 (5.6)          \<0.0001
  Procedural death                           947 (0.6)                  493 (0.5)          454 (0.7)           \<0.0001
  Vascular complications                     9392 (5.6)                 5815 (5.5)         3577 (5.8)          0.024
  Vascular complications requiring surgery   6810 (4.1)                 4344 (4.1)         2466 (4)            0.174
  Permanent pacemaker implantation           11 453 (6.9)               6980 (6.6)         4473 (7.2)          \<0.0001
  Transient ischemic attack                  570 (0.3)                  345 (0.3)          225 (0.4)           0.219
  Clinical stroke                            4634 (2.8)                 2866 (2.7)         1768 (2.9)          0.096
  Acute kidney injury                        26 264 (15.7)              17 432 (16.6)      8832 (14.3)         \<0.0001
  Acute kidney injury requiring dialysis     2934 (1.8)                 1811 (1.7)         1123 (1.8)          0.146
  Blood transfusion                          62 473 (37.5)              37 254 (35.4)      25 219 (40.9)       \<0.0001
  Cardiac tamponade                          1512 (0.9)                 985 (0.9)          527 (0.9)           0.084
  Discharge status, n (%)                    \<0.0001                                                          
  Discharged home                            114 714 (68.8)             77 727 (74)        36 987 (59.9)       
  Discharged SNF/NH/IC                       44 134 (26.5)              22 996 (21.9)      21 138 (34.3)       
  Length of stay, d, median (IQR)            8 (7)                      8 (7)              8 (8)               \<0.0001
  Cost of hospitalization, \$, mean (SD)     56 260 (41 280)            55 834 (40 937)    56 985 (41 849)     \<0.0001

AVR indicates aortic valve replacement; IC, intermediate care; IQR, interquartile range; NH, nursing home; SNF, skilled nursing facility.

Outcomes of Isolated AVR {#jah32569-sec-0016}
------------------------

Among the 166 809 patients who underwent AVR during the study period, 85 975 (51.5%) had isolated AVR. The majority of these patients (60.8%) were men. Baseline characteristics and in‐hospital outcomes of the unmatched groups of men and women who underwent isolated AVR are shown in Tables [S2](#jah32569-sup-0001){ref-type="supplementary-material"} and [S3](#jah32569-sup-0001){ref-type="supplementary-material"}. Propensity score matching yielded 28 237 matched pairs of male and female patients who underwent isolated AVR (Figure [2](#jah32569-fig-0002){ref-type="fig"}). Variables used in propensity matching are listed in Table [S1](#jah32569-sup-0001){ref-type="supplementary-material"}. Baseline characteristics were well matched between groups (Table [3](#jah32569-tbl-0003){ref-type="table-wrap"}, Figure [S1](#jah32569-sup-0001){ref-type="supplementary-material"}). After propensity matching, in‐hospital mortality remained significantly higher in women than in men (3.3% versus 2.9%, *P*=0.001; Table [4](#jah32569-tbl-0004){ref-type="table-wrap"}). Although in‐hospital mortality decreased among both men and women over time, the significant gap between men and women remained constant throughout the study period (Figure [3](#jah32569-fig-0003){ref-type="fig"}). Vascular complications and blood transfusions were more frequent in female than male patients (6% versus 5.6%, *P*=0.027; and 40.4% versus 33.9%, *P*\<0.001, respectively; Table [4](#jah32569-tbl-0004){ref-type="table-wrap"}). Rates of stroke, permanent pacemaker implantation, and acute kidney injury requiring dialysis were similar in male and female patients (2.4% versus 2.4%, *P*=0.99; 6.1% versus 6.3%, *P*=0.36; and 1.4% versus 1.3%, *P*=0.14, respectively). Length of stay was longer for women (10.1±9.6 versus 9.6±9 days, *P*\<0.001), and rates of nonhome discharge (skilled nursing facility, nursing home, or intermediate care) were higher for women (27.9% versus 19.6%, *P*\<0.001). Cost of hospitalization was similar for the 2 groups (\$50 111±24 372 for women versus \$49 774±34 701 for men, *P*=0.248).

![Study flow chart. NE indicates national estimate.](JAH3-6-e006370-g002){#jah32569-fig-0002}

###### 

Characteristics of Propensity Score--Matched Patients Undergoing Isolated Surgical AVR Between 2003 and 2014

  Characteristic                        Male (n=28 237)   Female (n=28 237)   *P* Value
  ------------------------------------- ----------------- ------------------- -----------
  Age, y, mean (SD)                     68 (13.3)         68 (14.1)           0.561
  Race, n (%)                           0.988                                 
  White                                 23 721 (84)       23 732 (84)         
  Black                                 1475 (5.2)        1469 (5.2)          
  Hispanic                              1591 (5.6)        1560 (5.5)          
  Medical comorbidity, n (%)                                                  
  Hypertension                          18 255 (64.6)     18 278 (64.7)       0.846
  Diabetes mellitus                     6757 (23.9)       6774 (24)           0.874
  Prior sternotomy                      1017 (3.6)        960 (3.4)           0.262
  Chronic pulmonary disease             5713 (20.2)       5708 (20.2)         0.966
  Atrial fibrillation/flutter           11 429 (40.5)     11 537 (40.9)       0.354
  Cardiogenic shock                     716 (2.5)         687 (2.4)           0.45
  Anemia                                5259 (18.6)       5293 (18.7)         0.72
  Coagulopathy                          6166 (21.8)       6136 (21.7)         0.767
  Conduction abnormalities              936 (3.3)         924 (3.3)           0.796
  Peripheral vascular disease           4586 (16.2)       4634 (16.4)         0.586
  Chronic renal disease                 2781 (9.8)        2782 (9.9)          0.99
  Coronary artery disease               6905 (24.5)       6943 (24.6)         0.714
  Metastatic cancer                     41 (0.1)          39 (0.1)            0.911
  Liver disease                         368 (1.3)         375 (1.3)           0.825
  Aortic prosthesis                                                           
  Bioprosthetic                         16 954 (60)       16 961 (60.1)       0.958
  Mechanical                            11 324 (40.1)     11 313 (40.1)       0.931
  Concomitant procedures, n (%)                                               
  Percutaneous coronary intervention    109 (0.4)         103 (0.4)           0.73
  IABP/LV assist device use             549 (1.9)         529 (1.9)           0.557
  Hospital characteristics, n (%)                                             
  Teaching hospital                     19 207 (68)       19 207 (68)         0.99
  Hospital bed size                     0.617                                 
  Small                                 1874 (6.6)        1868 (6.6)          
  Medium                                5075 (18)         5068 (17.9)         
  Large                                 21 288 (75.4)     21 301 (75.4)       
  Rural location                        1012 (3.6)        1029 (3.6)          0.719
  Nonelective admission status, n (%)   7957 (28.2)       7968 (28.2)         0.962
  Primary payer, n (%)                  0.165                                 
  Medicare/Medicaid                     19 489 (69)       19 301 (68.4)       
  Private including HMO                 7648 (27.1)       7818 (27.7)         
  Self‐pay/no charge/other              1100 (3.9)        1118 (4)            
  Median household income, n (%)                          0.866               
  0 to 25th percentiles                 6257 (22.2)       6232 (22.1)         
  26th to 50th percentiles              7303 (25.9)       7342 (26)           
  51st to 75th percentiles              7357 (26.1)       7352 (26)           
  76th to 100th percentiles             7320 (25.9)       7311 (25.9)         

AVR indicates aortic valve replacement; HMO, health maintenance organization; IABP, intra‐aortic balloon pump; LV, left ventricular.

###### 

In‐Hospital Outcomes of Propensity Score--Matched Patients Undergoing Isolated Surgical AVR Between 2003 and 2014

                                             Male (n=28 237)   Female (n=28 237)   *P* Value
  ------------------------------------------ ----------------- ------------------- -----------
  Clinical outcome, n (%)                                                          
  In‐hospital death                          806 (2.9)         943 (3.3)           0.001
  Procedural death                           87 (0.3)          117 (0.4)           0.042
  Vascular complications                     1581 (5.6)        1705 (6)            0.027
  Vascular complications requiring surgery   1178 (4.2)        1237 (4.4)          0.228
  Permanent pacemaker implantation           1686 (6)          1769 (6.3)          0.15
  Transient ischemic attack                  108 (0.4)         81 (0.3)            0.059
  Clinical stroke                            682 (2.4)         682 (2.4)           0.99
  Acute kidney injury                        3881 (13.7)       2968 (10.5)         \<0.0001
  Acute kidney injury requiring dialysis     404 (1.4)         363 (1.3)           0.144
  Blood transfusion                          9563 (33.9)       11 386 (40.4)       \<0.0001
  Cardiac tamponade                          267 (0.9)         209 (0.7)           0.009
  Discharge status, n (%)                    \<0.0001                              
  Discharged home                            21 831 (77.3)     19 342 (68.5)       
  Discharged SNF/NH/IC                       5545 (19.6)       7882 (27.9)         
  Length of stay, d, median (IQR)            7 (6)             7 (6)               \<0.0001
  Cost of hospitalization, \$, mean (SD)     49 774 (34 701)   50 111 (24 372)     0.248

AVR indicates aortic valve replacement; IC, intermediate care; IQR, interquartile range; NH, nursing home; SNF, skilled nursing facility.

![Trends of in‐hospital mortality following isolated surgical aortic valve replacement in men and women between 2003 and 2014.](JAH3-6-e006370-g003){#jah32569-fig-0003}

A subgroup analysis of the propensity score--matched cohorts showed that the differential impact of sex on in‐hospital mortality was consistent among subcohorts of patients stratified based on age (\<65 versus \>65 years); hospital teaching status; race; insurance status; and the presence of diabetes mellitus, peripheral vascular disease, or atrial fibrillation (Figure [S2](#jah32569-sup-0001){ref-type="supplementary-material"}).

Sensitivity Analysis {#jah32569-sec-0017}
--------------------

To further assess for residual confounding, a rule‐out approach to sensitivity analysis was used to illustrate how strongly a single unmeasured confounder would need to be associated with female sex and a significant outcome end point to fully explain our findings (Figure [S3](#jah32569-sup-0001){ref-type="supplementary-material"}).[16](#jah32569-bib-0016){ref-type="ref"} To fully explain the observed difference in blood transfusion rates between male and female patients undergoing AVR, a confounder would have to be 2 times more likely to be associated with female than male sex and, concurrently, increase the risk of blood transfusion by 6 times.

Discussion {#jah32569-sec-0018}
==========

The major findings of the current investigations are as follows. First, men undergo surgical AVR for AS more than women, Second, women who underwent AVR in the United States between 2003 and 2014 were older and had distinctive risk profiles and demographics compared with men. Third, women had higher unadjusted and adjusted in‐hospital mortality following AVR than men, and this was consistent over time. Fourth, after risk adjustment, women had more vascular complications and blood transfusions than men and were more likely to be discharged to a skilled nursing facility, nursing home, or intermediate care center.

The higher utilization of AVR in men compared with women in this study (63% versus 37%, *P*\<0.001) is consistent with previous studies.[17](#jah32569-bib-0017){ref-type="ref"}, [18](#jah32569-bib-0018){ref-type="ref"}, [19](#jah32569-bib-0019){ref-type="ref"} Several plausible explanations can be postulated from the existing literature. Regarding disparity in the incidence of AS, historical echocardiographic data showed that the risk of developing AS was 2‐fold higher in men than in women[20](#jah32569-bib-0020){ref-type="ref"}; however, nationwide claim‐based studies in hospitalized patients showed a less pronounced disparity in AS diagnosis between men and women. Among 113 847 patients admitted with an aortic valve disorder diagnosis in the United States, 55.1% were men.[21](#jah32569-bib-0021){ref-type="ref"} A similar study in Sweden showed that men constituted 52% of all patients newly diagnosed with AS.[22](#jah32569-bib-0022){ref-type="ref"} Even a lower incidence of new AS diagnosis in men was observed in a large Scottish registry of 19 733 patients, of whom 46.8% were men.[23](#jah32569-bib-0023){ref-type="ref"} Regarding disparity in referral for testing, women with AS were less likely to be seen by a specialist and less likely to be referred for testing.[19](#jah32569-bib-0019){ref-type="ref"} Regarding disparity in referral to surgery, women diagnosed with AS had unfavorable preoperative baseline characteristics compared with men at the time of presentation and thus were less likely to be referred to surgical treatment.[4](#jah32569-bib-0004){ref-type="ref"}, [9](#jah32569-bib-0009){ref-type="ref"}, [24](#jah32569-bib-0024){ref-type="ref"} Interestingly, this disparity in referral to valve replacement is not seen with the current TAVR practice; in the United States and Germany, women composed 52% and 55%, respectively, of all patients undergoing TAVR, respectively.[25](#jah32569-bib-0025){ref-type="ref"}, [26](#jah32569-bib-0026){ref-type="ref"} Furthermore, compared with women, men had much higher prevalence of coronary artery disease (52.7% versus 44.2%, *P*\<0.001) and were more likely to undergo coronary artery bypass grafting (42.8% versus 33.7%, *P*\<0.001). Although speculative, perhaps many men underwent AVR for lesser degrees of aortic valve disease at the time of coronary bypass, contributing to the larger number of men undergoing AVR overall. The disparity of AVR utilization in women seems to be more pronounced in the most recent year (Figure [1](#jah32569-fig-0001){ref-type="fig"}). This could be related to the introduction of TAVR. Since TAVR became commercially available in the United States in 2011, women have been referred more often to TAVR versus AVR compared with men (Figure [S4](#jah32569-sup-0001){ref-type="supplementary-material"}). This may explain the later divergence of utilization trends of AVR between men and women (Figure [1](#jah32569-fig-0001){ref-type="fig"}).

In line with the majority of previous studies, we found distinctive risk profiles for men and women undergoing AVR.[4](#jah32569-bib-0004){ref-type="ref"}, [6](#jah32569-bib-0006){ref-type="ref"}, [11](#jah32569-bib-0011){ref-type="ref"}, [12](#jah32569-bib-0012){ref-type="ref"}, [17](#jah32569-bib-0017){ref-type="ref"}, [27](#jah32569-bib-0027){ref-type="ref"} Women undergoing AVR (isolated or combined) were older and had more nonatherosclerotic comorbid conditions at presentation including hypertension, diabetes mellitus, chronic obstructive pulmonary disease, atrial fibrillation/flutter, and anemia compared with men. In contrast, men presented with higher incidences of coronary and peripheral arterial disease and prior sternotomies. The impact of sex on the pathophysiology of valvular heart disease has not been studied extensively. In addition, the focus of research on this topic has been to investigate sex differences in ventricular responses to pressure and volume overload posed by valvular disease rather than evaluating differences in the mechanism of AS itself.[28](#jah32569-bib-0028){ref-type="ref"} Nevertheless, 3 recent studies found important differences between men and women with regard to the development, extent, and progression of aortic valve calcifications supporting sex‐related differences in the mechanism of AS.[29](#jah32569-bib-0029){ref-type="ref"}, [30](#jah32569-bib-0030){ref-type="ref"}, [31](#jah32569-bib-0031){ref-type="ref"} Our findings of distinct risk profiles between men and women with AS at a community level support this notion and call for further research in sex‐specific disease mechanisms.

To date, there is no contemporary large‐scale study assessing sex‐related differences in clinical outcomes following AVR. Evidence from the available series conflicts with older studies showing no difference in post‐AVR mortality between men and women and more contemporary studies showing worse short‐ and long‐term outcomes in women compared with men (Table [S4](#jah32569-sup-0001){ref-type="supplementary-material"}). In this real‐world study of 166 809 patients, in‐hospital mortality was significantly higher in women compared with men following both combined AVR (odds ratio: 1.4; 95% confidence interval \[CI\], 1.36--1.49; *P*\<0.0001) and isolated AVR (unadjusted odds ratio: 1.3; 95% CI, 1.45--1.39; *P*\<0.0001; adjusted odds ratio: 1.2; 95% CI, 1.07--1.29; *P*=0.001). The higher mortality rate in women was consistent throughout the 12‐year study period and was seen among most subgroups of patients (Figure [S2](#jah32569-sup-0001){ref-type="supplementary-material"}). Compared with men, women had more vascular complications and blood transfusions but similar rates of stroke, permanent pacemaker implantation, and acute kidney injury requiring dialysis. Although cost of hospitalization was similar, resource utilization was higher for women because of the significantly higher need for intermediate care or skilled nursing after discharge (27.9% versus 19.6%, *P*\<0.001). This could be related to the higher incidence of vascular complications and blood transfusions in women but also could be related to the higher incidence of frailty among older women with AS.[32](#jah32569-bib-0032){ref-type="ref"}

The discussion of our findings would be incomplete without alluding to the emerging data demonstrating superior outcomes of TAVR in women compared with men and a higher magnitude of benefit of TAVR versus surgical AVR in women than in men.[1](#jah32569-bib-0001){ref-type="ref"}, [14](#jah32569-bib-0014){ref-type="ref"}, [24](#jah32569-bib-0024){ref-type="ref"}, [33](#jah32569-bib-0033){ref-type="ref"} A large report from the ACC/TVT registry examined sex differences among 11 808 patients who underwent TAVR and found no difference in in‐hospital mortality in women versus men after TAVR but significantly better 1‐year mortality in women versus men (adjusted hazard ratio: 0.73; 95% CI, 0.63--0.85; *P*\<0.001).[14](#jah32569-bib-0014){ref-type="ref"} Similarly, in a patient‐level meta‐analysis including 11 310 patients, women had similar mortality to men at 30 days but had significantly better long‐term survival (adjusted hazard ratio: 0.79; 95% CI, 0.73--0.86; *P*=0.001), despite higher rates of in‐hospital complications.[1](#jah32569-bib-0001){ref-type="ref"} A subgroup analysis of the PARTNER trial showed that women who underwent TAVR had better short‐term (6.8% versus 13.1%; *P*=0.07) and long‐term (hazard ratio: 0.67; 95% CI, 0.44--1.0; *P*=0.049) mortality compared with women who underwent AVR.[24](#jah32569-bib-0024){ref-type="ref"} Likewise, a subgroup analysis of the pivotal CoreValve trial showed superior 1‐year survival in women who underwent TAVR versus those who underwent AVR (12.7% versus 21.8%; *P*=0.03).[33](#jah32569-bib-0033){ref-type="ref"} It is worth noting that in this study, we found that ≈28% of isolated AVRs were performed during nonelective admissions (Table [3](#jah32569-tbl-0003){ref-type="table-wrap"}). Isolated AVR during a nonelective admission is associated with a 43% increase in cost (\$217 660±187 318 versus \$151 817±124 094, *P*\<0.001). Further studies are needed to assess the impact of procedural status (elective versus nonelective) on cost of AVR in the TAVR era.

Limitations {#jah32569-sec-0019}
-----------

This study has a number of limitations. First, the NIS is an administrative database that aims to gather data for billing purposes and can be limited by erroneous coding; however, the HCUP quality control measures should minimize these possibilities. Furthermore, the hard clinical end points used in our analysis are difficult to miscode. Second, the NIS allows detailed assessment of in‐hospital outcomes; however, certain laboratory and echocardiographic data as well as some procedural details such as aortic valve gradient, valve size, and ejection fractions are not captured. In addition, long‐term mortality data are unavailable in this database. Third, the potential for unmeasured confounders may bias the outcome results in the propensity score--matched cohorts; however, we believe that our rigorous propensity matching and the sensitivity analysis adequately addressed this selection bias.

Conclusion {#jah32569-sec-0020}
==========

In a contemporary nationwide analysis, AVR is performed less often in women then in men. Women also have worse in‐hospital mortality and are more likely to be discharged to a nursing home or intermediate care facility compared with men. These data, coupled with the accumulating evidence suggesting superiority of TAVR over AVR in women, underscore the need for a rigorous controlled trial specifically in female patients to properly study mortality differences between treatment modalities.
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**Table S1.** Variables Used for Propensity Score Matching
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**Table S3.** In‐Hospital Outcomes of Patients Undergoing Isolated Surgical Aortic Valve Replacement Between 2003 and 2014

**Table S4.** Summary of the Literature on Sex Disparity Following Surgical and Transcatheter Aortic Valve Replacement

**Figure S1.** Standardized mean differences before and after propensity score matching.

**Figure S2.** Subgroup analysis of sex disparity in in‐hospital mortality following isolated surgical aortic valve replacement (male used as a reference group).

**Figure S3.** Sensitivity analysis for required strength of an unmeasured confounder. Each line splits the area into 2: The upper right corner of the graph above the confines of a line represents all parameter combinations of an association between an unmeasured confounder and the treatment (aortic valve replacement \[AVR\] in female patients; *y*‐axis) with the outcome (blood transfusion; *x*‐axis) required to move the measured odds ratio (OR) to null. Conversely, the lower left corner represents all parameter combinations of an association between an unmeasured confounder and the treatment and outcome that would not move the measure OR to null.

**Figure S4.** Proportion of TAVR and SAVR among men and women who underwent aortic valve replacement since commercial approval of TAVR. SAVR indicates surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
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